William Ma Kowalczyk

William Ma Kowalczyk

Auto-generated profile, based on publicly available information

William Ma Kowalczyk

Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2010 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
SGSarit A Golub
Sarit A Golub
WKWilliam Ma Kowalczyk
William Ma Kowalczyk
CLCORINA T LELUTIU-WEINBERGER
CORINA T LELUTIU-WEINBERGER
JPJeffrey T Parsons
Jeffrey T Parsons
Objectives: Preexposure prophylaxis (PREP) is an emerging HIV prevention strategy; however, many fear it may lead to neglect of traditional risk reduction practices through behavioral disinhibition or risk compensation. Methods: Participants were 180 HIV-negative high-risk men who have sex with men recruited in New York City, who completed an Audio Computer Assisted Self Interview-administered survey between September 2007 and July 2009. Bivariate and multivariate logistic regression models were used to predict intention to use PREP and perceptions that PREP would decrease condom use. Results: Almost 70% (n = 124) of participants reported that they would be likely to use PREP if it were at least 80% effective in preventing HIV. Of those who would use PREP, over 35% reported that they would be likely to decrease condom use while on PREP. In multivariate analyses, arousal/pleasure barriers to condom use significantly predicted likelihood of PREP use (odds ratio = 1.71, P < 0.05) and risk perception motivations for condom use significantly predicted decreased condom use on PREP (odds ratio = 2.48, P < 0.05). Discussion: These data provide support for both behavioral disinhibition and risk compensation models and underscore the importance of developing behavioral interventions to accompany any wide-scale provision of PREP to high-risk populations.

20 June 2007 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
SCSandra D Comer
Sandra D Comer
MSMaria A Sullivan
Maria A Sullivan
RWRobert A Whittington
Robert A Whittington
SVSuzanne K Vosburg
Suzanne K Vosburg
WKWilliam J Kowalczyk
William J Kowalczyk
Abuse of prescription opioid medications has increased dramatically in the United States during the past decade, as indicated by a variety of epidemiological sources. However, few studies have systematically examined the relative reinforcing effects of commonly abused opioid medications. The current double-blind, placebo-controlled in-patient study was designed to compare the effects of intravenously delivered fentanyl (0, 0.0625, 0.125, 0.187, and 0.250 mg/70 kg), oxycodone (0, 6.25, 12.5, 25, and 50 mg/70 kg), morphine (0, 6.25, 12.5, 25, and 50 mg/70 kg), buprenorphine (0, 0.125, 0.5, 2, and 8 mg/70 kg), and heroin (0, 3.125, 6.25, 12.5, and 25 mg/70 kg) in morphine-maintained heroin abusers (N=8 completers maintained on 120 mg per day oral morphine in divided doses (30 mg q.i.d.)). All of the participants received all of the drugs tested; drugs and doses were administered in non-systematic order. All of the drugs produced statistically significant, dose-related increases in positive subjective ratings, such as ‘I feel a good drug effect’ and ‘I like the drug.’ In general, the order of potency in producing these effects, from most to least potent, was fentanyl>buprenorphine⩾heroin >morphine=oxycodone. In contrast, buprenorphine was the only drug that produced statistically significant increases in ratings of ‘I feel a bad drug effect’ and it was the only drug that was not self-administered above placebo levels at any dose tested. These data suggest that the abuse liability of buprenorphine in heroin-dependent individuals may be low, despite the fact that it produces increases in positive subjective ratings. The abuse liabilities of fentanyl, morphine, oxycodone, and heroin, however, appear to be similar under these experimental conditions.

1 March 2006 in The Journal of Pain
Verified
Journal Article
Closed access
WKWilliam J. Kowalczyk
William J. Kowalczyk
SESuzette M. Evans
Suzette M. Evans
ABAdam M. Bisaga
Adam M. Bisaga
MSMaria A. Sullivan
Maria A. Sullivan
SCSandra D. Comer
Sandra D. Comer

1 September 2019 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
LPLeigh V. Panlilio
Leigh V. Panlilio
SSSamuel W. Stull
Samuel W. Stull
WKWilliam J. Kowalczyk
William J. Kowalczyk
KPKarran A. Phillips
Karran A. Phillips
JSJennifer R. Schroeder
Jennifer R. Schroeder
KPKenzie L. Preston
Kenzie L. Preston

1 August 2015 in American Journal of Psychiatry
Verified
Journal Article
Closed access
WKWilliam J. Kowalczyk
William J. Kowalczyk
KPKarran A. Phillips
Karran A. Phillips
MJMichelle L. Jobes
Michelle L. Jobes
AKAshley P. Kennedy
Ashley P. Kennedy
UGUdi E. Ghitza
Udi E. Ghitza
KPKenzie L. Preston
Kenzie L. Preston

6 November 2017 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
KPKenzie L Preston
Kenzie L Preston
WKWilliam J Kowalczyk
William J Kowalczyk
KPKarran A Phillips
Karran A Phillips
MJMichelle L Jobes
Michelle L Jobes
MVMassoud Vahabzadeh
Massoud Vahabzadeh
DEDavid H Epstein
David H Epstein